Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …

Aims Extensive research regarding the association of troponin and prognosis in coronavirus
disease 2019 (COVID‐19) has been performed. However, data regarding natriuretic …

Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in
a variety of patient populations, with heterogeneous results regarding benefit and safety …

Aims VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and
vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) …

Importance The current recommendation is for at least 12 months of dual antiplatelet therapy
after implantation of a drug-eluting stent. However, the optimal duration of dual antiplatelet …

Background: The hybrid algorithm for chronic total occlusion (CTO) percutaneous coronary
intervention (PCI) was developed to improve procedural outcomes. Large, prospective …

Aims Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary
syndrome (ACS) but increases bleeding to a similar extent. We sought to determine the …

Background In acute myocardial infarction complicated by cardiogenic shock the use of
mechanical circulatory support devices remains controversial and data from randomized …

Background: Patients receiving oral anticoagulation (OAC) who undergo drug-eluting stent
(DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel …